SANOFI-AVENTIS has today
advised of the TGA approval of its
new antiarrhythmic treatment
Multaq (dronedarone) 400mg.
Multaq is indicated to reduce the
risk of cardiovascular
hospitalisation in patients with
paroxysmal or persistent atrial
fibrillation or atrial flutter, with a
recent episode and associated
cardiovascular risk factors, on top
of standard therapy.
The medication has been shown
to reduce the primary endpoint of
cardiovascular hospitalisation or
death from any cause by 24% in a
trial of 4628 patients.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.